These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28415831)

  • 21. Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response.
    Ziel E; Hermann G; Sen N; Bonomi P; Liptay MJ; Fidler MJ; Batus M; Warren WH; Chmielewski G; Sher DJ
    J Thorac Oncol; 2015 Oct; 10(10):1475-80. PubMed ID: 26398822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapy.
    Richlitzki C; Wiesweg M; Metzenmacher M; Guberina N; Pöttgen C; Hautzel H; Eberhardt WEE; Darwiche K; Theegarten D; Aigner C; Bölükbas S; Schuler M; Stuschke M; Guberina M
    Sci Rep; 2024 Jun; 14(1):13765. PubMed ID: 38877146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Neoadjuvant chemotherapy and chemoradiotherapy in locally advanced stage IIIA and IIIB of non-small-cell bronchial carcinoma (the Essen concept)].
    Eberhardt W
    Praxis (Bern 1994); 1997 Oct; 86(42):1647-53. PubMed ID: 9432686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer: a systematic review and practice guideline.
    Okawara G; Ung YC; Markman BR; Mackay JA; Evans WK;
    Lung Cancer; 2004 Apr; 44(1):1-11. PubMed ID: 15013578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
    Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
    Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Definitive chemotherapy and radiotherapy in patients with stage II non-small cell lung cancer: A population-based outcomes study.
    Sampath S; Hall M; Schultheiss TE
    Lung Cancer; 2015 Oct; 90(1):61-4. PubMed ID: 26231092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of chemoradiotherapy versus radiation alone in patients with inoperable locally advanced non-small-cell lung cancer: A meta-analysis and systematic review.
    Hung MS; Wu YF; Chen YC
    Medicine (Baltimore); 2019 Jul; 98(27):e16167. PubMed ID: 31277121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery.
    Lim HJ; Lee HY; Lee KS; Han J; Kwon OJ; Park K; Ahn YC; Kim BT; Shim YM
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):77-85. PubMed ID: 25374409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer.
    Choi NC; Carey RW; Daly W; Mathisen D; Wain J; Wright C; Lynch T; Grossbard M; Grillo H
    J Clin Oncol; 1997 Feb; 15(2):712-22. PubMed ID: 9053497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multimodality treatment with surgery for locally advanced non-small-cell lung cancer with n2 disease: a review article.
    Toyokawa G; Takenoyama M; Ichinose Y
    Clin Lung Cancer; 2015 Jan; 16(1):6-14. PubMed ID: 25220209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
    Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
    Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study.
    Casal Rubio J; Fírvida-Pérez JL; Lázaro-Quintela M; Barón-Duarte FJ; Alonso-Jáudenes G; Santomé L; Afonso-Afonso FJ; Amenedo M; Huidobro G; Campos-Balea B; López-Vázquez MD; Vázquez S
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):451-7. PubMed ID: 24352251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature.
    Tsujino K; Kurata T; Yamamoto S; Kawaguchi T; Kubo A; Isa S; Hasegawa Y; Ou SH; Takada M; Ando M
    J Thorac Oncol; 2013 Sep; 8(9):1181-9. PubMed ID: 23883782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiotherapy versus surgery within multimodality protocols for esophageal cancer--a meta-analysis of the randomized trials.
    Pöttgen C; Stuschke M
    Cancer Treat Rev; 2012 Oct; 38(6):599-604. PubMed ID: 22116018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of surgery in N2 non-small cell lung cancer.
    DeCamp MM; Ashiku S; Thurer R
    Clin Cancer Res; 2005 Jul; 11(13 Pt 2):5033s-5037s. PubMed ID: 16000610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group.
    Nyman J; Friesland S; Hallqvist A; Seke M; Bergström S; Thaning L; Lödén B; Sederholm C; Wagenius G
    Lung Cancer; 2009 Jul; 65(1):62-7. PubMed ID: 19081652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
    Liu D; Zheng X; Chen J; Liu G; Xu Y; Shen Y; Xie L; Zhao W; Jiang G; Fan M
    Lung Cancer; 2015 Sep; 89(3):249-54. PubMed ID: 26118463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.